NVO - Amgen cut at Leerink on heavy obesity expectations
2024-02-07 09:34:00 ET
More on Amgen
- Amgen Inc. (AMGN) Q4 2023 Earnings Call Transcript
- Amgen: Debt-Funded Buybacks Constrains Future Gains Per Share
- Amgen: Accelerating The Business And Dividend Growth
- Amgen Non-GAAP EPS of $4.71 beats by $0.12, revenue of $8.2B beats by $90M
- Amgen’s obesity prospects in focus ahead of Q4 results